CYTOSORBENTS CORP (CTSO) Fundamental Analysis & Valuation

NASDAQ:CTSO • US23283X2062

Current stock price

0.66 USD
+0.02 (+3.45%)
At close:
0.66 USD
0 (0%)
After Hours:

This CTSO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTSO Profitability Analysis

1.1 Basic Checks

  • CTSO had negative earnings in the past year.
  • CTSO had a negative operating cash flow in the past year.
  • In the past 5 years CTSO always reported negative net income.
  • In the past 5 years CTSO always reported negative operating cash flow.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -23.14%, CTSO is in line with its industry, outperforming 47.28% of the companies in the same industry.
  • The Return On Equity of CTSO (-117.35%) is worse than 66.30% of its industry peers.
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • CTSO's Gross Margin of 77.02% is amongst the best of the industry. CTSO outperforms 88.04% of its industry peers.
  • CTSO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CTSO Health Analysis

2.1 Basic Checks

  • CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CTSO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CTSO has been increased compared to 5 years ago.
  • Compared to 1 year ago, CTSO has a worse debt to assets ratio.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -8.72, we must say that CTSO is in the distress zone and has some risk of bankruptcy.
  • CTSO has a Altman-Z score of -8.72. This is in the lower half of the industry: CTSO underperforms 78.80% of its industry peers.
  • CTSO has a Debt/Equity ratio of 1.61. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of CTSO (1.61) is worse than 80.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACC11.11%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.11 indicates that CTSO has no problem at all paying its short term obligations.
  • CTSO has a worse Current ratio (2.11) than 61.41% of its industry peers.
  • CTSO has a Quick Ratio of 1.71. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
  • CTSO has a Quick ratio (1.71) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.71
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CTSO Growth Analysis

3.1 Past

  • CTSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.35%, which is quite impressive.
  • The Revenue has decreased by -8.97% in the past year.
  • The Revenue has been growing slightly by 7.36% on average over the past years.
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CTSO will show a very strong growth in Revenue. The Revenue will grow by 26.86% on average per year.
EPS Next Y55.26%
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year-3.8%
Revenue Next 2Y2.36%
Revenue Next 3Y8.04%
Revenue Next 5Y26.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. CTSO Valuation Analysis

4.1 Price/Earnings Ratio

  • CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CTSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CTSO's earnings are expected to grow with 22.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-173.17%
EPS Next 3Y22.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTSO Dividend Analysis

5.1 Amount

  • CTSO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTSO Fundamentals: All Metrics, Ratios and Statistics

CYTOSORBENTS CORP

NASDAQ:CTSO (3/20/2026, 8:00:01 PM)

After market: 0.66 0 (0%)

0.66

+0.02 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-02
Earnings (Next)03-25
Inst Owners26.23%
Inst Owner Change2.91%
Ins Owners9.21%
Ins Owner Change1.36%
Market Cap41.45M
Revenue(TTM)34.35M
Net Income(TTM)-10.59M
Analysts80
Price Target5.36 (712.12%)
Short Float %3.78%
Short Ratio26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.89%
Min EPS beat(2)-5.03%
Max EPS beat(2)158.82%
EPS beat(4)2
Avg EPS beat(4)27.26%
Min EPS beat(4)-116.73%
Max EPS beat(4)158.82%
EPS beat(8)6
Avg EPS beat(8)21.99%
EPS beat(12)7
Avg EPS beat(12)13.46%
EPS beat(16)7
Avg EPS beat(16)-7.04%
Revenue beat(2)1
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-7.32%
Max Revenue beat(2)2.1%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)2.1%
Revenue beat(8)2
Avg Revenue beat(8)-5.15%
Revenue beat(12)4
Avg Revenue beat(12)-4.39%
Revenue beat(16)5
Avg Revenue beat(16)-5.31%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B 4.6
P/tB 7.64
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-2.84
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.55
BVpS0.14
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.02%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.94%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 1.71
Altman-Z -8.72
F-Score4
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)280.25%
Cap/Depr(5y)336.32%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y55.26%
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%
Revenue Next Year-3.8%
Revenue Next 2Y2.36%
Revenue Next 3Y8.04%
Revenue Next 5Y26.87%
EBIT growth 1Y32.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOSORBENTS CORP / CTSO Fundamental Analysis FAQ

What is the fundamental rating for CTSO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTSO.


What is the valuation status of CYTOSORBENTS CORP (CTSO) stock?

ChartMill assigns a valuation rating of 1 / 10 to CYTOSORBENTS CORP (CTSO). This can be considered as Overvalued.


How profitable is CYTOSORBENTS CORP (CTSO) stock?

CYTOSORBENTS CORP (CTSO) has a profitability rating of 1 / 10.


Can you provide the financial health for CTSO stock?

The financial health rating of CYTOSORBENTS CORP (CTSO) is 2 / 10.